{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:41:00Z","timestamp":1791394860448,"version":"4.3.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"BioNexus KC 20-7 Nexus of Animal and Human Health Research Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01334-5","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T18:30:09Z","timestamp":1754073009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-0923","authenticated-orcid":false,"given":"Mobina","family":"Golmohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2265","authenticated-orcid":false,"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram","family":"Albayyadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Sholehrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moath","family":"Albliwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Hajj","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-7975","authenticated-orcid":false,"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-6550","authenticated-orcid":false,"given":"Majid","family":"Jaberi-Douraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"1334_CR1","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/jcm10184088","volume":"10","author":"M Kleber","year":"2021","unstructured":"Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma\u2014a promising key to therapy. J Clin Med. 2021;10:4088.","journal-title":"J Clin Med"},{"key":"1334_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","volume":"5","author":"M Harris","year":"2004","unstructured":"Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004;5:292\u2013302.","journal-title":"Lancet Oncol"},{"key":"1334_CR3","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.3390\/jcm10194593","volume":"10","author":"M Hosny","year":"2021","unstructured":"Hosny M, Verkleij CPM, van der Schans J, Frerichs KA, Mutis T, Zweegman S, et al. Current state of the art and prospects of T cell-redirecting bispecific antibodies in multiple myeloma. J Clin Med. 2021;10:4593.","journal-title":"J Clin Med"},{"key":"1334_CR4","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"1334_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13:125.","journal-title":"J Hematol Oncol"},{"key":"1334_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00966-9","volume":"14","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, van de Donk N, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024;14:24.","journal-title":"Blood Cancer J"},{"key":"1334_CR7","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/JCO.2023.41.16_suppl.8015","volume":"41","author":"M Jaberi-Douraki","year":"2023","unstructured":"Jaberi-Douraki M, Xu X, Faiman B, Wyckoff G, Riviere J, Khouri J, et al. Disparities in multiple myeloma: a global perspective on drug toxicity trends. ASCO J Clin Oncol. 2023;41:8015.","journal-title":"ASCO J Clin Oncol"},{"key":"1334_CR8","doi-asserted-by":"crossref","unstructured":"Jaberi-Douraki M, Xu X, Dima D, Ailawadhi S, Anwer F, Mazzoni S, et al. Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study. Blood cancer J. 2024;14:223.","DOI":"10.1038\/s41408-024-01206-4"},{"key":"1334_CR9","doi-asserted-by":"crossref","unstructured":"Jaberi-Douraki M, Raza S, Xu X, Ramachandran RA, Golmohammadi M, Sholehrasa H, et al. Comparative analysis of adverse event profiles for CAR-T cell therapies and bispecific antibodies in lymphoma. J Clin Oncol. 2025;43.","DOI":"10.1200\/JCO.2025.43.16_suppl.e19019"},{"key":"1334_CR10","doi-asserted-by":"publisher","first-page":"S295","DOI":"10.1016\/S2152-2650(23)02082-7","volume":"23","author":"M Jaberi-Douraki","year":"2023","unstructured":"Jaberi-Douraki M, Xu X, Ramachandran R, Faiman B, Anwer F, Samaras C, et al. Global disparities in multiple myeloma: examining adverse events and drug toxicity trends. Clin Lymphoma, Myeloma Leuk. 2023;23:S295\u20136.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"1334_CR11","unstructured":"SERVICES USDOHAH. Common Terminology Criteria for Adverse Events (CTCAE). 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"1334_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"1334_CR13","doi-asserted-by":"publisher","first-page":"e20044","DOI":"10.1200\/JCO.2023.41.16_suppl.e20044","volume":"41","author":"P Venkatesh","year":"2023","unstructured":"Venkatesh P, Atrash S, Paul B, Alkharabsheh O, Afrough A, Mahmoudjafari Z, et al. Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed\/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT). J Clin Oncol. 2023;41:e20044.","journal-title":"J Clin Oncol"},{"key":"1334_CR14","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1182\/blood-2024-207295","volume":"144","author":"R Rifkin","year":"2024","unstructured":"Rifkin R, Schade H, Simmons G, Yasenchak C, Fowler J, Lin TS, et al. Optec: a phase 2 study to evaluate outpatient step-up administration of teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM): updated results. Blood. 2024;144:4753.","journal-title":"Blood"},{"key":"1334_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12185-024-03884-z","volume":"121","author":"T Ishida","year":"2025","unstructured":"Ishida T, Kuroda Y, Matsue K, Komeno T, Ishiguro T, Ishikawa J, et al. A phase 1\/2 study of teclistamab, a humanized BCMA\u00d7CD3 bispecific Ab in Japanese patients with relapsed\/refractory MM. Int J Hematol. 2025;121:222\u201331.","journal-title":"Int J Hematol"},{"key":"1334_CR16","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1200\/JCO.2023.41.16_suppl.8049","volume":"41","author":"R Firestone","year":"2023","unstructured":"Firestone R, Shekarkhand T, Patel D, Tan CRC, Hultcrantz M, Lesokhin AM, et al. Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies. J Clin Oncol. 2023;41:8049.","journal-title":"J Clin Oncol"},{"key":"1334_CR17","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1334_CR18","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.1200\/JCO.2023.41.16_suppl.8038","volume":"41","author":"M Sun","year":"2023","unstructured":"Sun M, Qiu L, Wei Y, Jin J, Li X, Liu X, et al. Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:8038.","journal-title":"J Clin Oncol"},{"key":"1334_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1182\/blood-2021-144921","volume":"138","author":"JA Zonder","year":"2021","unstructured":"Zonder JA, Richter J, Bumma N, Brayer J, Hoffman JE, Bensinger WI, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2021;138:160.","journal-title":"Blood"},{"key":"1334_CR20","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:2702\u201312.","journal-title":"J Clin Oncol"},{"key":"1334_CR21","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","volume":"41","author":"HC Lee","year":"2023","unstructured":"Lee HC, Bumma N, Richter JR, Dhodapkar MV, Hoffman JE, Suvannasankha A, et al. LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:8006.","journal-title":"J Clin Oncol"},{"key":"1334_CR22","doi-asserted-by":"publisher","first-page":"10140","DOI":"10.1182\/blood-2022-159969","volume":"140","author":"N Bumma","year":"2022","unstructured":"Bumma N, Richter J, Brayer J, Zonder JA, Dhodapkar M, Shah MR, et al. Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed\/refractory multiple myeloma: a phase 1\/2 first-in-human study. Blood. 2022;140:10140\u20131.","journal-title":"Blood"},{"key":"1334_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. Anti\u2013B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38:775\u201383.","journal-title":"J Clin Oncol"},{"key":"1334_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-134063","volume":"136","author":"SJ Harrison","year":"2020","unstructured":"Harrison SJ, Minnema MC, Lee HC, Spencer A, Kapoor P, Madduri D, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM). Blood. 2020;136:28\u20139.","journal-title":"Blood"},{"key":"1334_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood-2019-122895","volume":"134","author":"LJ Costa","year":"2019","unstructured":"Costa LJ, Wong SW, Berm\u00fadez A, de la Rubia J, Mateos M-V, Ocio EM, et al. First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134:143.","journal-title":"Blood"},{"key":"1334_CR26","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","volume":"40","author":"A D\u2019Souza","year":"2022","unstructured":"D\u2019Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2022;40:3576\u201386.","journal-title":"J Clin Oncol"},{"key":"1334_CR27","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodriguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"1334_CR28","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025;12:e269\u201381.","journal-title":"Lancet Haematol"},{"key":"1334_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1182\/blood-2021-146868","volume":"138","author":"AY Krishnan","year":"2021","unstructured":"Krishnan AY, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodriguez-Otero P, et al. Updated phase 1 results from MonumenTAL-1: first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138:158.","journal-title":"Blood"},{"key":"1334_CR30","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, van de Donk NW, Rodr\u00edguez-Otero P, Mateos MV, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8036.","journal-title":"J Clin Oncol"},{"key":"1334_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"SCA Trudel","year":"2021","unstructured":"Trudel SCA, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, Lesokhin A, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138:157.","journal-title":"Blood"},{"key":"1334_CR32","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","volume":"41","author":"YCMD Cohen","year":"2023","unstructured":"Cohen YCMD, Gatt ME, Sebag M, Kim K, Min CK, Oriol A, et al. First results from the RedirecTT-1 study with teclistamab (tec)+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8002.","journal-title":"J Clin Oncol"},{"key":"1334_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392:138\u201349.","journal-title":"N Engl J Med"},{"key":"1334_CR34","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","volume":"41","author":"BR Dholaria","year":"2023","unstructured":"Dholaria BR, Weisel K, Mateos MV, Goldschmidt H, Martin TG, Morillo D, et al. Talquetamab (tal)+ daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results. J Clin Oncol. 2023;41:8003.","journal-title":"J Clin Oncol"},{"key":"1334_CR35","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood-2023-187706","volume":"142","author":"J Matous","year":"2023","unstructured":"Matous J, Biran N, Perrot A, Berdeja JG, Dorritie K, Van Elssen J, et al. Talquetamab plus pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 Study. Blood. 2023;142:1014.","journal-title":"Blood"},{"key":"1334_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1536867X0900900208","volume":"9","author":"M Chatfield","year":"2009","unstructured":"Chatfield M, Mander A. The Skillings-Mack test (Friedman test when there are missing data). Stata J. 2009;9:299\u2013305.","journal-title":"Stata J"},{"key":"1334_CR37","doi-asserted-by":"publisher","unstructured":"Gewers FL, Ferreira GR, Arruda HFD, Silva FN, Comin CH, Amancio DR, et al. Principal component analysis: a natural approach to data exploration. ACM Comput Surv. 2021. https:\/\/doi.org\/10.1145\/344775.","DOI":"10.1145\/344775"},{"key":"1334_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s43586-022-00192-w","volume":"2","author":"M Greenacre","year":"2022","unstructured":"Greenacre M, Groenen PJF, Hastie T, D\u2019Enza AI, Markos A, Tuzhilina E. Principal component analysis. Nat Rev Methods Prim. 2022;2:100. https:\/\/doi.org\/10.1038\/s43586-022-00192-w.","journal-title":"Nat Rev Methods Prim"},{"key":"1334_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/14786440109462720","volume":"2","author":"K Pearson","year":"1901","unstructured":"Pearson K. LIII. On lines and planes of closest fit to systems of points in space. Lond Edinb Dublin Philos Mag J Sci. 1901;2:559\u201372.","journal-title":"Lond Edinb Dublin Philos Mag J Sci"},{"key":"1334_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116.","journal-title":"Blood Cancer J"},{"key":"1334_CR41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/79802","volume":"1","author":"G Yu","year":"2000","unstructured":"Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000;1:252\u20136.","journal-title":"Nat Immunol"},{"key":"1334_CR42","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","volume":"37","author":"E Terpos","year":"2023","unstructured":"Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2023;37:1175\u201385.","journal-title":"Leukemia"},{"key":"1334_CR43","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.3390\/jcm10215190","volume":"10","author":"THA Tvedt","year":"2021","unstructured":"Tvedt THA, Vo AK, Bruserud O, Reikvam H. Cytokine release syndrome in the immunotherapy of hematological malignancies: the biology behind and possible clinical consequences. J Clin Med. 2021;10:5190.","journal-title":"J Clin Med"},{"key":"1334_CR44","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2022-159381","volume":"140","author":"S Trudel","year":"2022","unstructured":"Trudel S, Bahlis NJ, Spencer A, Kaedbey R, Rodriguez Otero P, Harrison SJ, et al. editor Pretreatment with tocilizumab prior to the CD3 bispecific cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) showed a marked reduction in cytokine release syndrome incidence and severity. Blood. 2022;140:1363\u20135.","journal-title":"Blood"},{"key":"1334_CR45","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov. 2023;4:440\u201351.","journal-title":"Blood Cancer Discov"},{"key":"1334_CR46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11899-024-00740-z","volume":"19","author":"D Pan","year":"2024","unstructured":"Pan D, Richter J. Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma. Curr Hematol Malig Rep. 2024;19:237\u201345.","journal-title":"Curr Hematol Malig Rep"},{"key":"1334_CR47","doi-asserted-by":"crossref","unstructured":"Rees JH. Management of immune effector cell-associated neurotoxicity syndrome (ICANS). In: Kroger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT\/EHA CAR-T cell handbook. Springer Nature Switzerland AG Cham; 2022. pp. 141\u20135.","DOI":"10.1007\/978-3-030-94353-0_27"},{"key":"1334_CR48","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/03007995.2024.2387183","volume":"40","author":"C Schinke","year":"2024","unstructured":"Schinke C, Dhakal B, Mazzoni S, Shenoy S, Scott SA, Richards T, et al. Real-world experience with clinical management of talquetamab in relapsed\/refractory multiple myeloma: a qualitative study of US healthcare providers. Curr Med Res Opin. 2024;40:1705\u201311.","journal-title":"Curr Med Res Opin"},{"key":"1334_CR49","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1530\/EJE-20-0732","volume":"183","author":"RHH Groenwold","year":"2020","unstructured":"Groenwold RHH, Dekkers OM. Missing data: the impact of what is not there. Eur J Endocrinol. 2020;183:E7\u20139.","journal-title":"Eur J Endocrinol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01334-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01334-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01334-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:58:39Z","timestamp":1757336319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01334-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1334"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01334-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SR received an honorarium as an advisory board for Pfizer, Prothena Biosciences, KiTE pharma Nexcella and Janssen and received research funding (outside of this study) from Nexcella Inc, Poseida Therapeutics and Janssen. JK: Consultancy and honoraria: Janssen, GPCR therapeutics, and Prothena. LW is a local principal investigator for Pfizer and Abbvie clinical trials and received honorarium for advisory board meeting for Janssen\/J&J Consulting. DH is supported by the NCI (R01CA281756-01A1) and the Pentecost Family Myeloma Research Center and reports research funding from Bristol-Myers Squibb, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech; Consulting or advisory role for Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma, AstraZeneca, and Karyopharm. FA served as the local principal investigator for Allogene Therapeutics, Bristol Myers Squibb, Celgene, and GlaxoSmithKline and served as the advisor and speaker for Bristol Myers Squibb\/Celgene. Other authors declare non-relevant declare non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}